Journey Advisory Group LLC Sells 169 Shares of Amgen Inc. $AMGN

Journey Advisory Group LLC decreased its position in Amgen Inc. (NASDAQ:AMGN) by 2.0% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 8,374 shares of the medical research company’s stock after selling 169 shares during the quarter. Journey Advisory Group LLC’s holdings in Amgen were worth $2,338,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in AMGN. Brighton Jones LLC grew its stake in shares of Amgen by 23.5% in the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after buying an additional 5,226 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Amgen by 40.2% in the 1st quarter. GAMMA Investing LLC now owns 11,753 shares of the medical research company’s stock valued at $3,662,000 after buying an additional 3,369 shares in the last quarter. Avior Wealth Management LLC grew its stake in shares of Amgen by 32.8% in the 1st quarter. Avior Wealth Management LLC now owns 2,483 shares of the medical research company’s stock valued at $774,000 after buying an additional 613 shares in the last quarter. Matrix Asset Advisors Inc. NY grew its stake in shares of Amgen by 4.6% in the 1st quarter. Matrix Asset Advisors Inc. NY now owns 97,314 shares of the medical research company’s stock valued at $30,318,000 after buying an additional 4,292 shares in the last quarter. Finally, Buck Wealth Strategies LLC grew its stake in shares of Amgen by 20.4% in the 1st quarter. Buck Wealth Strategies LLC now owns 33,718 shares of the medical research company’s stock valued at $10,505,000 after buying an additional 5,712 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Up 1.0%

AMGN opened at $298.81 on Monday. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $335.88. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 7.24. The stock has a market capitalization of $160.87 billion, a price-to-earnings ratio of 24.43, a P/E/G ratio of 2.64 and a beta of 0.49. The business has a 50 day moving average of $287.14 and a 200-day moving average of $286.99.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, August 5th. The medical research company reported $6.02 earnings per share for the quarter, beating the consensus estimate of $5.28 by $0.74. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The company had revenue of $9.18 billion during the quarter, compared to analysts’ expectations of $8.86 billion. During the same period in the prior year, the business earned $4.97 earnings per share. Amgen’s revenue for the quarter was up 9.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. As a group, sell-side analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 12th. Stockholders of record on Friday, August 22nd were given a $2.38 dividend. This represents a $9.52 annualized dividend and a dividend yield of 3.2%. The ex-dividend date of this dividend was Friday, August 22nd. Amgen’s dividend payout ratio is currently 77.84%.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Raymond James Financial began coverage on Amgen in a research report on Wednesday, September 3rd. They set a “market perform” rating for the company. Wall Street Zen raised shares of Amgen from a “hold” rating to a “buy” rating in a report on Sunday. Bank of America upped their price objective on shares of Amgen from $261.00 to $272.00 and gave the stock an “underperform” rating in a report on Friday, September 26th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $305.00 price objective on shares of Amgen in a report on Tuesday, June 24th. Finally, Piper Sandler upped their price objective on shares of Amgen from $328.00 to $342.00 and gave the stock an “overweight” rating in a report on Monday, August 25th. Seven investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $305.50.

Insider Activity at Amgen

In related news, SVP Nancy A. Grygiel sold 1,267 shares of the company’s stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total value of $376,286.33. Following the completion of the transaction, the senior vice president directly owned 7,209 shares in the company, valued at approximately $2,141,000.91. This represents a 14.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.69% of the company’s stock.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.